Biopharmaceutical Innovation: The Patent Imperative Under Siege
核心洞察
U.S. biopharmaceutical R&D investment reaches $150 billion annually, yielding cures for Hepatitis C (搜索), GLP-1s for weight loss, COVID-19 vaccines (搜索), and CAR-T therapies (搜索) for previously untreatable cancers.
Less than 22% of the 18,500 recognized diseases worldwide have FDA-approved treatments, highlighting vast unmet medical need.
A new FDA-approved medicine takes on average 10 years and more than $2.5 billion to develop, with only about 12% of candidates reaching approval.
U.S. biopharmaceutical innovation—fueled by $150 billion per year in private sector R&D investment—is delivering unprecedented medical breakthroughs, yet faces a growing assault from patent-hostile legislation, government price controls, and global IP waivers, according to an Issue Brief published by the Center for American Principles. The analysis warns that policymakers, "misled by patent myths and manipulated data," are undermining the very intellectual property framework that has enabled cures for Hepatitis C (搜索), GLP-1 receptor agonists (搜索) for weight loss, COVID-19 vaccines (搜索), HIV prevention at virtually 100% effectiveness, stem cell therapies, gene editing, and CAR-T therapies (搜索) for previously untreatable cancers.
Despite these successes, the unmet medical need remains staggering. According to nonprofit rare disease advocacy and research group Every Cure (搜索), "less than 22% of the 18.5K recognized diseases in the world have FDA-approved treatments." Meanwhile, ARPA-H (搜索) Director Alicia Jackson noted in a May 2026 interview that "we see many, many U.S. folks going [to China] for their clinical trials network at this point because it's half the cost and two to five times faster."
The Economics of Drug Development
A new medicine approved by the U.S. Food and Drug Administration takes on average 10 years and more than $2.5 billion to develop. Only about 12% of potential drugs make it through the rigorous process to become FDA approved. The Association for Accessible Medicines, representing generic drug producers, acknowledges: "Drug research is costly and patent protection gives brand-name manufacturers [time] to recover research & development costs—costs that generic manufacturers do not have to recoup."
Where patent rights are sufficiently available and reliable, they provide a basis for investment in the long, risky, and expensive work of curing disease. Patent rights to novel inventions and discoveries, rooted in the U.S. Constitution and codified in U.S. law, enable the significant capital expenditures necessary to advance the state of the art at every stage of drug discovery.
Beyond Single-Product, Single-Patent Thinking
The analysis challenges the perspective that only a single patent should apply to a single product. An innovative medicine combines solutions to a range of challenges—each of which must be overcome to safely and effectively deliver a therapeutic benefit. Pharmaceutical IP expert Brent Bellows explains that patent "claims are anchored tightly to the science: compositions, formulations, methods of treatment, routes of administration and FDA-approved indications."
Innovation does not end with the early-stage discovery of a promising new chemical entity or biologic. The composition of matter patent starts the innovator's foundational 20-year term of exclusivity running, typically years before a product reaches market. Subsequent patents represent new solutions to specific biomedical challenges: identifying a chemical or biological remedy that acts on a disease target; matching it with a delivery system; zeroing in on a dosage balancing effect against toxicity; and developing specialized know-how to reproduce and deliver the medicine at scale.
Post-Approval Innovation and the USPTO (搜索) Study
Post-approval innovations—often dismissed by critics as trivial—can be highly advantageous to patients. These investments make medicines safer and more effective for broader patient groups, enable pediatric use, or uncover new therapeutic indications, all through costly research and trials at the innovator's expense.
In a 2024 study, the USPTO (搜索) provided a clear empirical analysis that thoroughly debunked anti-patent claims. For its Drug Patent and Exclusivity Study, the Office selected 25 medicines—among them the "most prescribed" and "top grossing" prescription medicines—that were emblematic of the innovation lifecycle. The USPTO found that none of the medicines studied was afforded more than 3 to 16 years of total market exclusivity, well short of the 20-year patent term. The report stated: "Such improvements, when deemed patentable, are entitled to patent protection, which is limited in scope to the patentable improvement. Importantly, once the original patent expires, the public may use the technology covered by the expired patent."
The inescapable takeaway, according to the analysis, is that activists manipulated data to inflate the effects of patents and other exclusive rights on competition. The ETHIC Act and similar bills that relied on data manipulation and false activist claims, the brief concludes, "should be left on the shelf, not American innovation."